News

Healthtech Startup Avammune Bags $12 Mn From Capital 2B, Others

Publications

AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model.
Avijit Goswami, Barnali Deb, Sandeep Goyal, Abhishek Gosavi, Mukund Mali, Ashwita M. Martis, Princy Khurana, Mukesh Gangar, Digambar Raykar, Ankita Mohanty and Aditya Kulkarni

Molecules. October 2022, 27, 6721

Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy.
Mukesh Gangar, Sandeep Goyal, Digambar Raykar, Princy Khurana, Ashwita M. Martis, Avijit Goswami, Ishani Ghoshal, Ketul V. Patel, Yadav Nagare, Santosh Raikar, Apurba Mukherjee, Rajath Cyriac, Jean-François Paquin, Aditya Kulkarni

Bioorganic Chemistry. December 2021, 0045-2068/© 2021 Elsevier Inc.

Conference Abstracts

1041 Discovery of a potential first-in-class small molecule inhibitor of ADAR1 p150 which demonstrates strong anti-tumor efficacy in B16F10 syngeneic melanoma mode
Avijit Goswami, Barnali Deb, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Aditya Kulkarni

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1148; DOI:10.1136/jitc-2023-SITC2023.1041

Abstract 3244: AVA-NP-695, a potent and selective ENPP1 inhibitor, abrogates tumor metastasis in 4T1 syngeneic tumor model and demonstrates strong tumor regression when combined with radiation
Aditya Kulkarni, Avijit Goswami, Sandeep Goyal, Princy Khurana, Ishani Ghoshal

Journal: Cancer Research Cancer Res (2023) 83 (7_Supplement): 3095. https://doi.org/10.1158/1538-7445.AM2023-3095

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics